Advertisement

Clinical and Translational Oncology

, Volume 21, Issue 2, pp 167–177 | Cite as

CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study

  • X. Zhang
  • J. Zhou
  • D.-D. Zhu
  • J. Huang
  • J.-H. Sun
  • T.-F. Li
  • C.-S. Shi
  • Z.-C. Sun
  • Q.-M. Hou
  • Z.-Y. Peng
  • W.-Q. Yu
  • J.-S. Ji
  • W.-J. Gu
  • G.-H. Zhou
  • X.-X Xie
  • X.-H. Guo
  • G.-H. Cao
  • Z.-H. Yu
  • H.-H. Xu
  • J. Fang
  • S.-H. Ying
  • W.-H. Hu
  • W.-B. Ji
  • J. Han
  • X. Wu
  • J.-P. Zheng
  • J. Luo
  • Y.-T. Chen
  • T.-Y. Hu
  • L. Li
  • H.-J. Hu
  • H.-J. DuEmail author
  • G.-L. ShaoEmail author
Research Article
  • 124 Downloads

Abstract

Purpose

To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.

Methods

367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1–2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.

Results

There was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1–3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1–3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.

Conclusion

DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.

Keywords

Drug-eluting beads transarterial chemoembolization (DEB-TACE) Efficacy Safety Previous cTACE treatment Liver cancer 

Notes

Acknowledgements

This work was supported by the National Nature Science Foundation of China (81371658) and Zhejiang Provincial Natural Science Foundation of China (LZ18H180001).

Funding

This work was supported by the National Nature Science Foundation of China (81371658) and Zhejiang Provincial Natural Science Foundation of China (LZ18H180001).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional ethics committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

12094_2018_1902_MOESM1_ESM.pdf (166 kb)
Supplementary material 1 (PDF 165 kb)

References

  1. 1.
    Recio-Boiles A, Babiker HM. Cancer, Liver. StatPearls. Treasure Island (FL)2017.Google Scholar
  2. 2.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.  https://doi.org/10.3322/caac.21262.CrossRefGoogle Scholar
  3. 3.
    Chen P, Yuan P, Chen B, Sun J, Shen H, Qian Y. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(1):75–85.  https://doi.org/10.1016/j.clinre.2016.05.013.CrossRefGoogle Scholar
  4. 4.
    European Association For The Study Of The. L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.  https://doi.org/10.1016/j.jhep.2011.12.001.CrossRefGoogle Scholar
  5. 5.
    Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.  https://doi.org/10.1002/hep.24199.CrossRefGoogle Scholar
  6. 6.
    Ludwig JM, Zhang D, Xing M, Kim HS. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. Eur Radiol. 2017;27(5):2031–41.  https://doi.org/10.1007/s00330-016-4548-3.CrossRefGoogle Scholar
  7. 7.
    Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2014;20(45):17206–17.  https://doi.org/10.3748/wjg.v20.i45.17206.CrossRefGoogle Scholar
  8. 8.
    Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, Xiang BD, et al. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45(2):190–200.  https://doi.org/10.1111/hepr.12450.CrossRefGoogle Scholar
  9. 9.
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.  https://doi.org/10.1055/s-0030-1247132.CrossRefGoogle Scholar
  10. 10.
    Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012;57(6):1258–67.  https://doi.org/10.1016/j.jhep.2012.07.025.CrossRefGoogle Scholar
  11. 11.
    Sangro B, D’Avola D, Inarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opin Pharmacother. 2011;12(7):1057–73.  https://doi.org/10.1517/14656566.2011.545346.CrossRefGoogle Scholar
  12. 12.
    Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22–31.  https://doi.org/10.1159/000368142.CrossRefGoogle Scholar
  13. 13.
    Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48(6):571–7.  https://doi.org/10.1016/j.dld.2016.02.005.CrossRefGoogle Scholar
  14. 14.
    Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244–50.  https://doi.org/10.1016/j.jhep.2012.07.017.CrossRefGoogle Scholar
  15. 15.
    Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.  https://doi.org/10.1007/s00270-009-9711-7.CrossRefGoogle Scholar
  16. 16.
    Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, et al. DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: a pilot study. Gut Liver. 2013;7(1):89–95.  https://doi.org/10.5009/gnl.2013.7.1.89.CrossRefGoogle Scholar
  17. 17.
    Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(5):920–5.  https://doi.org/10.1111/jgh.12439.CrossRefGoogle Scholar
  18. 18.
    Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016;17(8):510–7.  https://doi.org/10.1111/1751-2980.12380.CrossRefGoogle Scholar
  19. 19.
    Jang JH, Lee JW, Hong JT, Jin YJ. Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. J Hepatocell Carcinoma. 2015;2:123–9.  https://doi.org/10.2147/JHC.S44380.Google Scholar
  20. 20.
    Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147–63.  https://doi.org/10.1146/annurev.immunol.021908.132629.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  • X. Zhang
    • 1
  • J. Zhou
    • 2
  • D.-D. Zhu
    • 3
  • J. Huang
    • 4
  • J.-H. Sun
    • 12
  • T.-F. Li
    • 5
  • C.-S. Shi
    • 6
  • Z.-C. Sun
    • 7
  • Q.-M. Hou
    • 8
  • Z.-Y. Peng
    • 1
  • W.-Q. Yu
    • 9
  • J.-S. Ji
    • 10
  • W.-J. Gu
    • 11
  • G.-H. Zhou
    • 12
  • X.-X Xie
    • 13
  • X.-H. Guo
    • 14
  • G.-H. Cao
    • 15
  • Z.-H. Yu
    • 16
  • H.-H. Xu
    • 17
  • J. Fang
    • 18
  • S.-H. Ying
    • 1
  • W.-H. Hu
    • 19
  • W.-B. Ji
    • 20
  • J. Han
    • 21
  • X. Wu
    • 22
  • J.-P. Zheng
    • 23
  • J. Luo
    • 23
  • Y.-T. Chen
    • 23
  • T.-Y. Hu
    • 9
  • L. Li
    • 3
  • H.-J. Hu
    • 22
  • H.-J. Du
    • 24
    Email author
  • G.-L. Shao
    • 23
    Email author
  1. 1.Interventional Radiology DepartmentThe First Affiliated Hospital, Zhejiang UniversityHangzhouChina
  2. 2.Department of RadiologyHangzhou Cancer HospitalHangzhouChina
  3. 3.Department of Liver OncologyNingbo No. 2 HospitalNingboChina
  4. 4.Department of Hepatobiliary SurgeryNingbo Medical Center Lihuili Easter HospitalNingboChina
  5. 5.Department of RadiologyBeilun District People’s Hospital of NingboNingboChina
  6. 6.Department of InterventionRuian People’s Hospital, The Third Affiliated Hospital of Wenzhou Medical UniversityRuianChina
  7. 7.Department of RadiologyThe First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Hospital of TCMHangzhouChina
  8. 8.Department of RadiologyXixi Hospital of Hangzhou, Hangzhou 6th People’s HospitalHangzhouChina
  9. 9.Department of InterventionZhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeHangzhouChina
  10. 10.Department of RadiologyLishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical UniversityLishuiChina
  11. 11.Department of InterventionJiaxing Second HospitalJiaxingChina
  12. 12.Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment CenterThe First Affiliated Hospital, Zhejiang UniversityHangzhouChina
  13. 13.Interventional CenterXinchang People’s HospitalXinchangChina
  14. 14.Department of InterventionJinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang UniversityJinhuaChina
  15. 15.Department of RadiologyShulan (Hangzhou) HospitalHangzhouChina
  16. 16.Department of Vascular and Interventional RadiologyThe Affiliated Hospital of Medical School of Ningbo UniversityNingboChina
  17. 17.Division of Digestive EndoscopyYueqing City People’s HospitalYueqingChina
  18. 18.Department of Hepatobiliary SurgeryQuzhou People’s HospitalQuzhouChina
  19. 19.Department of InterventionThe First Provincial Wenzhou Hospital of Zhejiang, The First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina
  20. 20.Department of RadiologyTaizhou Hospital of Zhejiang ProvinceLinhaiChina
  21. 21.Department of InterventionJiaxing First HospitalJiaxingChina
  22. 22.Department of RadiologySir Run Run Shaw Hospital, Zhejiang University School of MedicineHangzhouChina
  23. 23.Department of InterventionZhejiang Cancer HospitalHangzhouChina
  24. 24.Department of InterventionDongyang People’s HospitalDongyangChina

Personalised recommendations